MRNS stock on watch as EU grants more time in review of seizure candidate (NASDAQ:MRNS)
seekingalpha.com
finance
2022-06-01 13:22:40

John Kevin/iStock via Getty Images The U.S.-based commercial-stage company Marinus Pharmaceuticals (NASDAQ:MRNS) announced on Wednesday that the European regulators agreed to the company's request to allow additional four months to submit data for the review of its seizure candidate ganaxolone. In 2021, Marinus (MRNS) sought European authorization for ganaxolone for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder. The marketing authorization application ('MAA') is currently undergoing the standard review of European Medicines Agency ('EMA').
